Cargando…

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia

Mutations or deregulated expression of the components of the spliceosome can influence the splicing pattern of several genes and contribute to the development of tumors. In this context, we report that the spliceosome modulator sudemycin induces selective cytotoxicity in primary chronic lymphocytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xargay-Torrent, Sílvia, López-Guerra, Mónica, Rosich, Laia, Montraveta, Arnau, Roldán, Jocabed, Rodríguez, Vanina, Villamor, Neus, Aymerich, Marta, Lagisetti, Chandraiah, Webb, Thomas R., López-Otín, Carlos, Campo, Elias, Colomer, Dolors
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673195/ https://www.ncbi.nlm.nih.gov/pubmed/26068951

Ejemplares similares

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma
por: Rosich, Laia, et al.
Publicado: (2014)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells
por: López-Guerra, Mónica, et al.
Publicado: (2019)

Sudemycin E influences alternative splicing and changes chromatin modifications
por: Convertini, Paolo, et al.
Publicado: (2014)

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
por: Montraveta, Arnau, et al.
Publicado: (2014)

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
por: Giménez, Neus, et al.
Publicado: (2019)

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
por: Giménez, Neus, et al.
Publicado: (2019)

Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6
por: Thurman, Morgan, et al.
Publicado: (2017)

Novel Tools for Diagnosis and Monitoring of AML
por: Guijarro, Francesca, et al.
Publicado: (2023)

Chronic lymphocytic leukemia and prolymphocytic leukemia. Two coins or two sides of the same coin?
por: Magnano, Laura, et al.
Publicado: (2020)

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
por: Silkenstedt, Elisabeth, et al.
Publicado: (2019)

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
por: Gimenez, Neus, et al.
Publicado: (2020)

A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses
por: Araujo-Ayala, Ferran, et al.
Publicado: (2023)

Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
por: Kyei, George B., et al.
Publicado: (2018)

Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution
por: Rivero, Andrea, et al.
Publicado: (2021)

Detection of chromothripsis‐like patterns with a custom array platform for chronic lymphocytic leukemia
por: Salaverria, Itziar, et al.
Publicado: (2015)

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
por: Mozas, Pablo, et al.
Publicado: (2018)

Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
por: Bastidas‐Mora, Gabriela, et al.
Publicado: (2021)

Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates
por: Shi, Yihui, et al.
Publicado: (2015)

Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
por: López-Oreja, Irene, et al.
Publicado: (2021)

Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia
por: Ferreira, Pedro G., et al.
Publicado: (2014)

Protein-Structure Assisted Optimization of 4,5-Dihydroxypyrimidine-6-Carboxamide Inhibitors of Influenza Virus Endonuclease
por: Beylkin, Diane, et al.
Publicado: (2017)

An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications
por: Shi, Yihui, et al.
Publicado: (2020)

SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies
por: Delgado, Julio, et al.
Publicado: (2020)

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms
por: Nadeu, Ferran, et al.
Publicado: (2020)

Serum alkaline phosphatase relates to cardiovascular risk markers in children with high calcium-phosphorus product
por: Xargay-Torrent, Sílvia, et al.
Publicado: (2018)

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
por: Nadeu, F, et al.
Publicado: (2018)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Giné, Eva, et al.
Publicado: (2022)

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
por: Vidal-Crespo, Anna, et al.
Publicado: (2020)

Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas
por: Fraile, Julia M., et al.
Publicado: (2013)

Factors associated with the perception of the problem of scarce potable water available for domestic use in the Nazas-Aguanaval river basin, Mexico
por: López Santiago, Marco Andrés, et al.
Publicado: (2023)

Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact
por: Mozas, Pablo, et al.
Publicado: (2020)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
por: Karvaly, Gellért Balázs, et al.
Publicado: (2022)

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
por: Valero, Juan Garcia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4r7v0gi6i68cr86umlb10a0grv